Fingolimod treatment in multiple sclerosis leads to increased macular volume.
about
Fingolimod for relapsing-remitting multiple sclerosisFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceFingolimod: a review of its use in relapsing-remitting multiple sclerosis.Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknownTargeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.Continuing fingolimod after development of macular edema: A case report.Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis.Development of a semi-automatic segmentation method for retinal OCT images tested in patients with diabetic macular edemaDefining Disease Activity and Response to Therapy in MS.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.High-Resolution Spectral Domain-Optical Coherence Tomography in Multiple Sclerosis, Part II - the Total Macular Volume. The First Follow-Up Study over 2 Years.Benign Multiple Sclerosis is Associated with Reduced Thinning of the Retinal Nerve Fiber and Ganglion Cell Layers in Non-Optic-Neuritis Eyes.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis.Sphingolipids role in the regulation of inflammatory response: From leukocyte biology to bacterial infection.
P2860
Q24185882-76020666-D397-4B10-B814-9F984FEF6643Q26752466-A977EBD9-D173-4F12-92E0-1C225B34F211Q30838717-B64E3413-51BD-466D-AECC-0A568B6566F7Q33875468-E6AC85FD-4823-4A09-8650-84A5CA1CB822Q34364844-A7C1C9CB-5EFE-4B12-BDCB-9057F452CC2EQ34368552-B2813650-D25E-46A7-A40F-1A1390ED6FDBQ34936918-98285E93-197A-4116-AAD6-2831223746FAQ35080093-13F7DFC1-EC42-4D0C-A7CA-487A77CE2269Q36357501-41077808-C1C3-4496-98DF-789B4A3F0928Q38172961-43A9D31B-83D8-44A5-A60A-686E41AB633BQ38534132-07223ADB-8F00-4CC4-A115-9B65240080A8Q38639875-B3E67CF9-4784-4248-A43D-FB3D3E842B62Q38869471-91FA232F-003D-4432-B37A-CE4D59475E40Q38915115-E11AD0E9-87FA-4457-A604-9C2A81EF6FE7Q41772469-6E473A56-558A-43FC-8767-99FCB6843BCEQ42133746-58608B7A-A746-4D31-9521-FB89912FF7C9Q47868767-27B1206E-AB60-481E-BAC9-784D5A5B0AE7Q48539254-24356DB8-8600-4FD5-830D-80F6044E5891Q49972804-5D2FC9DD-B12E-4BB0-BA1A-4B71A77E3189
P2860
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@ast
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@en
type
label
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@ast
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@en
prefLabel
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@ast
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@en
P2093
P2860
P1433
P1476
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
@en
P2093
Ari J Green
Jeffrey M Gelfand
Rachel Nolan
P2860
P304
P356
10.1212/WNL.0B013E31827B9132
P407
P577
2012-12-05T00:00:00Z